Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 3, 2003, Pages 910-916

  Hecht, David W ^a,b   Osmolski, J R ^a  

^a HINES VA HOSPITAL   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; CEFOXITIN; CLINAFLOXACIN; CLINDAMYCIN; GARENOXACIN; GATIFLOXACIN; IMIPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SITAFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BACTEROIDES VULGATUS; DRUG SCREENING; DRUG SENSITIVITY; FUSOBACTERIUM; GRAM NEGATIVE ANAEROBIC BACTERIA; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; PEPTOSTREPTOCOCCUS; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; CHICAGO; CULTURE MEDIA; FLUOROQUINOLONES; INDOLES; MICROBIAL SENSITIVITY TESTS; QUINOLONES;

EID: 0037416971     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.3.910-916.2003     Document Type: Article

References (27)

1. Aldridge, K. E. 1995. The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections. Am. J. Surg. 169:2S-7S.
2. Aldridge, K. E., D. Ashcraft, K. Cambre, C. L. Pierson, S. G. Jenkins, and J. E. Rosenblatt. 2001. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob. Agents Chemother. 45:1238-1243.
3. Appelbaum, P. C. 1999. Quinolone activity against anaerobes. Drugs 58(Suppl. 2):60-64.
4. Bassetti, M., L. M. Dembry, P. A. Farrel, D. A. Callan, and V. T. Andriole. 2002. Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and β-lactams against gram-positive clinical isolates. Antimicrob, Agents Chemother. 46:234-238.
5. Betriu, C., M. Gomez, M. L. Palau, A. Sanchez, and J. J. Picazo. 1999. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents. Antimicrob. Agents Chemother. 43:2320-2322.
6. Bryskier, A. 2001. Anti-anaerobic activity of antibacterial agents. Expert Opin. Investig. Drugs 10:239-267.
7. Ednie, L. M., M. R. Jacobs, and P. C. Appelbaum. 1998. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob. Agents Chemother. 42:2459-2462.
8. Edwards, R., C. V. Hawkyard, M. T. Garvey, and D. Greenwood. 1999. Prevalence and degree of expression of the carbapenemase gene (cfiA) among clinical isolates of Bacteroides fragilis in Nottingham, UK. J. Antimicrob. Chemother. 43:273-276.
9. Fix, A. M., M. A. Pfaller, D. J. Biedenbach, M. L. Beach, and R. N. Jones. 2001. Comparative antimicrobial spectrum and activity of BMS284756 (T3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development. Int. J. Antimicrob. Agents 18:141-145.
10. Fosse, T., I. Madinier, C. Hitzig, and Y. Charbit. 1999. Prevalence of betalactamase-producing strains among 149 anaerobic gram-negative rods isolated from periodontal pockets. Oral Microbiol. Immunol. 14:352-357.
11. Fung-Tomc, J., L. Valera, B. Minassian, D. Bonner, and E. Gradelski. 2001. Activity of the novel des-fluoro(6) quinolone BMS-284756 against methicillin-susceptible and -resistant staphylococci. J. Antimicrob. Chemother. 48: 735-738.
12. Fung-Tomc, J. C., B. Minassian, B. Kolek, E. Huczko, L. Aleksunes, T. Stickle, T. Washo, E. Gradelski, L. Valera, and D. P. Bonner. 2000. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob. Agents Chemother. 44:3351-3356.
13. Giamarellou, H. 2000. Anaerobic infection therapy. Int. J. Antimicrob. Agents 16:341-346.
14. Hecht, D. W., J. R. Osmolski, and J. P. O'Keefe. 1993. Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals. Clin. Infect. Dis. 16(Suppl. 4):S357-S360.
15. Hoellman, D. B., L. M. Kelly, M. R. Jacobs, and P. C. Appelbaum. 2001. Comparative antianaerobic activity of BMS 284756. Antimicrob. Agents Chemother. 45:589-592.
16. Labbe, A. C., A. M. Bourgault, J. Vincelette, P. L. Turgeon, and F. Lamothe. 1999. Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada. Antimicrob. Agents Chemother. 43:2517-2519.
17. Lubbe, M. M., P. L. Botha, and L. J. Chalkley. 1999. Comparative activity of eighteen antimicrobial agents against anaerobic bacteria isolated in South Africa. Eur. J. Clin. Microbiol. Infect. Dis. 18:46-54.
18. Montravers, P., R. Gauzit, C. Muller, J. P. Marmuse, A. Fichelle, and J. M. Desmonts. 1996. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin. Infect. Dis. 23:486-494.
19. National Committee for Clinical Laboratory Standards. 1997. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Document M11A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
20. Nguyen, M. H., V. L. Yu, A. J. Morris, L. McDermott, M. W. Wagener, L. Harrell, and D. R. Snydman. 2000. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin. Infect. Dis. 30:870-876.
21. Rhomberg, P. R., D. J. Biedenbach, and R. N. Jones. 2001. Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacterjejuni, Helicobacter pylori and Legionella spp. Diagn. Microbiol. Infect. Dis. 40:45-49.
22. Snydman, D. R., N. V. Jacobus, L. A. McDermott, S. Supran, G. J. Cuchural, Jr., S. Finegold, L. Harrell, D. W. Hecht, P. Iannini, S. Jenkins, C. Pierson, J. Rihs, and S. L. Gorbach. 1999. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob. Agents Chemother. 43:2417-2422.
23. Soki, J., E. Urban, I. Szoke, E. Fodor, and E. Nagy. 2000. Prevalence of the carbapenemase gene (cfiA) among clinical and normal flora isolates of Bacteroides species in Hungary. J. Med. Microbiol. 49:427-430.
24. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1994. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob. Agents Chemother. 38:2471-2476.
25. Stark, C. A., C. Edlund, S. Sjostedt, G. Kristensen, and C. E. Nord. 1993. Antimicrobial resistance in human oral and intestinal anaerobic microfloras. Antimicrob. Agents Chemother. 37:1665-1669.
26. Weller, T. M., J. M. Andrews, G. Jevons, and R. Wise. 2002. The in vitro activity of BMS-284756, a new des-fluorinated quinolone. J. Antimicrob. Chemother. 49:177-184.
27. Wexler, H. M., E. Molitoris, D. Molitoris, and S. M. Finegold. 1996. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob. Agents Chemother. 40:2232-2235.